TABLE 1.
Baseline demographics and characteristics of HIV− negative hepatitis B core antibody-positive (anti-HBc+) cohort stratified by hepatitis B surface antibody (anti-HBs) status
| Total (N = 17 266) | Anti-HBs−/unknown (N = 7174) | Anti-HBs+ (N = 10 092) | |
|---|---|---|---|
| Age | 63 (60-67) | 64 (61-67) | 63 (60-66) |
| Male, N (%) | 16 902 (98) | 7042 (98) | 9860 (98) |
| Race, N (%) | |||
| White | 7882 (46) | 3155 (44) | 4727 (47) |
| Black | 8097 (47) | 3480 (49) | 4617 (46) |
| Other | 271 (2) | 111 (2) | 160 (2) |
| Unknown | 976 (6) | 412 (6) | 564 (6) |
| Genotype, N (%) | |||
| 1 | 14 372 (83) | 6051 (84) | 8321 (82) |
| 2 | 1444 (8) | 560 (8) | 884 (9) |
| 3 | 838 (5) | 303 (4) | 535 (5) |
| 4–6 | 171 (1) | 64 (1) | 107 (1) |
| Cirrhosis, N (%) | 4148 (24) | 1643 (23) | 2505 (25) |
| Decompensated cirrhosis, N (%) | 509 (3) | 219 (3) | 290 (3) |
| Hepatocellular carcinoma, N (%) | 37 (0) | 16 (0) | 21 (0) |
| Alcoholism, N (%) | 1386 (8) | 553 (8) | 833 (8) |
| Alcohol misuse, N (%)a | 1376 (8) | 548 (8) | 828 (8) |
| Baseline total bilirubin (mg/dL), median (IQR) | 0.9 (0.6-1.1) | 0.9 (0.6-1.0) | 1.0 (0.6-1.1) |
| Baseline ALT (IU/mL), median (IQR) | 67 (34-81) | 67 (35-80) | 67 (34-82) |
| HCV direct-acting antiviral, N (%) | |||
| PrOD | 1711 (10) | 753 (10) | 958 (9) |
| EBR/GZR | 1358 (8) | 615 (9) | 743 (7) |
| SOF/DAC | 242 (1) | 87 (1) | 155 (2) |
| SOF/LDV | 10 737 (62) | 4471 (62) | 6266 (62) |
| SOF/RBV | 1802 (11) | 694 (10) | 1108 (11) |
| SOF/SMV | 914 (5) | 363 (5) | 551 (5) |
| SOF/VEL | 502 (3) | 191 (3) | 311 (3) |
| HCV DAA duration days, median (IQR) | 85 (75-85) | 85 (75-85) | 85 (75-84) |
| Follow-up to 12 wk post-treatment, N (%) | 13 390 (78) | 5536 (77) | 7854 (78) |
| SVR12 tested, N (%) | 10 675 (62) | 4364 (61) | 6311 (63) |
| SVR12 (among tested), N (%) | 9944 (93) | 4079 (93) | 5865 (93) |
SOF/LDV, sofosobuvir/ledipasvir; PrOD, paritaprevir/ritonavir, ombitasvir +dasabuvir; SOF/DAC, sofosbuvir/ daclatasvir; EBR/GZR, elbasvir/grazoprevir; SOF/VEL, sofosbuvir/velpatasvir; DAA, direct-acting antiviral; IQR, interquartile range; SVR, sustained virologic response; ALT, alanine aminotransferase.
a
Alcohol misuse was identified with the alcohol use disorder identification test, and score ≥4 for males and ≥3 for females indicates hazardous drinking.